Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GANXNASDAQ:HOOKNASDAQ:IMMXNASDAQ:IMUX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.89+4.4%$2.20$0.89▼$4.04$50.13M0.14281,967 shs268,438 shsHOOKHookipa Pharma$0.92-11.0%$1.55$0.88▼$10.50$11.05M0.7174,369 shs133,924 shsIMMXImmix Biopharma$1.65+2.5%$1.82$1.26▼$3.13$45.74M0.26131,617 shs32,857 shsIMUXImmunic$1.11+4.2%$1.09$0.92▼$2.11$99.99M1.89607,419 shs724,083 shs10 Stocks Set to Soar in Spring 2025Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics+4.42%-9.57%-3.08%-18.53%-51.41%HOOKHookipa Pharma-11.00%-24.86%-34.99%-52.99%-87.94%IMMXImmix Biopharma+2.48%-9.84%+1.85%-25.00%-43.88%IMUXImmunic+4.23%-7.50%-4.31%+8.82%-9.02%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGANXGain Therapeutics3.2235 of 5 stars3.65.00.00.03.40.80.6HOOKHookipa Pharma1.801 of 5 stars3.23.00.00.00.61.70.6IMMXImmix Biopharma2.9254 of 5 stars3.53.00.00.03.61.70.6IMUXImmunic2.6226 of 5 stars3.64.00.00.02.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGANXGain Therapeutics 3.17Buy$8.20333.86% UpsideHOOKHookipa Pharma 2.33Hold$23.002,409.00% UpsideIMMXImmix Biopharma 3.00Buy$7.00324.24% UpsideIMUXImmunic 3.22Buy$12.671,041.14% UpsideCurrent Analyst Ratings BreakdownLatest IMMX, HOOK, IMUX, and GANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/28/2025GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/25/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/17/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/7/2025GANXGain TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform ➝ Sector Outperform$12.002/26/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.002/21/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/20/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.002/10/2025IMMXImmix BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.001/10/2025HOOKHookipa PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral1/7/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGANXGain Therapeutics$50K1,002.65N/AN/A$0.97 per share1.95HOOKHookipa Pharma$43.95M0.25N/AN/A$9.08 per share0.10IMMXImmix BiopharmaN/AN/AN/AN/A$0.81 per shareN/AIMUXImmunicN/AN/AN/AN/A$0.64 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGANXGain Therapeutics-$22.27M-$0.92N/AN/AN/AN/A-203.91%-128.05%5/13/2025 (Estimated)HOOKHookipa Pharma-$81.58M-$3.52N/AN/AN/A-86.74%-33.31%-21.65%5/8/2025 (Estimated)IMMXImmix Biopharma-$15.43M-$0.77N/AN/AN/AN/A-102.68%-80.89%5/8/2025 (Estimated)IMUXImmunic-$93.61M-$1.23N/AN/AN/AN/A-169.55%-118.96%4/3/2025 (Estimated)Latest IMMX, HOOK, IMUX, and GANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/4/2025N/AIMMXImmix Biopharma-$0.25N/AN/AN/AN/AN/A4/3/2025N/AIMUXImmunic-$0.24-$0.2350+$0.0050N/AN/AN/A3/27/2025Q4 2024GANXGain Therapeutics-$0.18-$0.11+$0.07-$0.11N/AN/A3/24/2025Q4 2024IMMXImmix Biopharma-$0.25-$0.16+$0.09-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGANXGain TherapeuticsN/AN/AN/AN/AN/AHOOKHookipa PharmaN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGANXGain Therapeutics0.042.992.99HOOKHookipa PharmaN/A3.263.26IMMXImmix BiopharmaN/A3.473.47IMUXImmunicN/A2.712.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGANXGain Therapeutics11.97%HOOKHookipa Pharma63.88%IMMXImmix Biopharma11.26%IMUXImmunic51.82%Insider OwnershipCompanyInsider OwnershipGANXGain Therapeutics11.70%HOOKHookipa Pharma3.30%IMMXImmix Biopharma48.90%IMUXImmunic3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGANXGain Therapeutics2026.53 million23.42 millionOptionableHOOKHookipa Pharma5612.06 million11.66 millionOptionableIMMXImmix Biopharma927.72 million14.06 millionOptionableIMUXImmunic7090.08 million87.38 millionOptionableIMMX, HOOK, IMUX, and GANX HeadlinesRecent News About These CompaniesD. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX)April 3 at 2:53 AM | americanbankingnews.comImmunic's (IMUX) "Buy" Rating Reaffirmed at D. Boral CapitalApril 2 at 8:02 AM | marketbeat.comEQS-News: Immunic, Inc. to Participate in Scientific and Industry Conferences in AprilApril 1 at 9:18 AM | markets.businessinsider.comImmunic, Inc. to Participate in Scientific and Industry Conferences in AprilApril 1 at 6:30 AM | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average Price Target from BrokeragesMarch 31 at 1:31 AM | americanbankingnews.comImmunic (IMUX) Has a New Rating from William BlairMarch 30, 2025 | markets.businessinsider.comContrasting 180 Life Sciences (NASDAQ:ATNF) and Immunic (NASDAQ:IMUX)March 30, 2025 | americanbankingnews.comImmunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of "Buy" from BrokeragesMarch 29, 2025 | marketbeat.comFY2026 Earnings Forecast for Immunic Issued By William BlairMarch 29, 2025 | americanbankingnews.comWilliam Blair Forecasts Immunic FY2026 EarningsMarch 28, 2025 | marketbeat.comWilliam Blair Estimates Immunic FY2025 EarningsMarch 28, 2025 | americanbankingnews.comBrokers Set Expectations for Immunic FY2025 EarningsMarch 27, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Earns Outperform Rating from Analysts at William BlairMarch 27, 2025 | americanbankingnews.comImmunic Sees Unusually High Options Volume (NASDAQ:IMUX)March 26, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Coverage Initiated by Analysts at William BlairMarch 26, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Immunic (IMUX) with Outperform RecommendationMarch 26, 2025 | msn.comStockNews.com Downgrades Immunic (NASDAQ:IMUX) to SellMarch 20, 2025 | marketbeat.comImmunic management to meet virtually with Piper SandlerMarch 18, 2025 | markets.businessinsider.comImmunic provides MS research update – ICYMIMarch 14, 2025 | proactiveinvestors.comImmunic provides MS research update – ICYMIMarch 14, 2025 | proactiveinvestors.comImmunic (NASDAQ:IMUX) Upgraded by StockNews.com to Hold RatingMarch 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMX, HOOK, IMUX, and GANX Company DescriptionsGain Therapeutics NASDAQ:GANX$1.89 +0.08 (+4.42%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$1.83 -0.06 (-3.17%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Hookipa Pharma NASDAQ:HOOK$0.92 -0.11 (-11.00%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.90 -0.02 (-1.71%) As of 08:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Immix Biopharma NASDAQ:IMMX$1.65 +0.04 (+2.48%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$1.66 +0.01 (+0.30%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Immunic NASDAQ:IMUX$1.11 +0.05 (+4.23%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$1.06 -0.05 (-4.05%) As of 09:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
